|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/352 | |
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Number of the document | 2710137 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12755115.8 |
| Date of filing the European patent application | 2012-03-09 | |
| (97) | Date of publication of the European application | 2014-03-26 |
| (45) | Date of publication and mention of the grant of the patent | 2018-09-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/028412 |
| Date | 2012-03-09 |
| (87) | Number | WO 2012/122444 |
| Date | 2012-09-13 |
| (30) | Number | Date | Country code |
| 201161451395 P | 2011-03-10 | US |
| (72) |
EAGLE, Craig J., US
DEES, H. Craig, US
WACHTER, Eric A., US
SINGER, Jamie, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
Provectus Pharmatech, Inc., 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932, US |
| (54) | A COMBINATION OF ROSE BENGAL AND ANTI-CTLA4 ANTIBODY FOR USE IN THE TREATMENT OF CANCER |
| A COMBINATION OF ROSE BENGAL AND ANTI-CTLA4 ANTIBODY FOR USE IN THE TREATMENT OF CANCER |